{"id":"https://openalex.org/W2890715470","doi":"https://doi.org/10.1093/cid/ciy747","title":"Pharmacokinetics, Safety, and Efficacy of an Allometric Miltefosine Regimen for the Treatment of Visceral Leishmaniasis in Eastern African Children: An Open-label, Phase II Clinical Trial","display_name":"Pharmacokinetics, Safety, and Efficacy of an Allometric Miltefosine Regimen for the Treatment of Visceral Leishmaniasis in Eastern African Children: An Open-label, Phase II Clinical Trial","publication_year":2018,"publication_date":"2018-08-28","ids":{"openalex":"https://openalex.org/W2890715470","doi":"https://doi.org/10.1093/cid/ciy747","mag":"2890715470","pmid":"https://pubmed.ncbi.nlm.nih.gov/30188978","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/6481997"},"language":"en","primary_location":{"id":"doi:10.1093/cid/ciy747","doi":"https://doi.org/10.1093/cid/ciy747","is_oa":true,"landing_page_url":"https://doi.org/10.1093/cid/ciy747","pdf_url":"https://academic.oup.com/cid/article-pdf/68/9/1530/28520743/ciy747.pdf","source":{"id":"https://openalex.org/S72350973","display_name":"Clinical Infectious Diseases","issn_l":"1058-4838","issn":["1058-4838","1537-6591"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Infectious Diseases","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://academic.oup.com/cid/article-pdf/68/9/1530/28520743/ciy747.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5065378109","display_name":"Jane Mbui","orcid":"https://orcid.org/0000-0002-8759-5689","observed_orcids":["https://orcid.org/0000-0002-8759-5689"]},"institutions":[{"id":"https://openalex.org/I2841861","display_name":"Kenya Medical Research Institute","ror":"https://ror.org/04r1cxt79","country_code":"KE","type":"facility","lineage":["https://openalex.org/I2841861"]}],"countries":["KE"],"is_corresponding":false,"raw_author_name":"Jane Mbui","raw_affiliation_strings":["Centre for Clinical Research, Kenya Medical Research Institute, Nairobi"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Centre for Clinical Research, Kenya Medical Research Institute, Nairobi","institution_ids":["https://openalex.org/I2841861"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000504924","display_name":"Joseph Okao Olobo","orcid":"https://orcid.org/0000-0001-5148-8876","observed_orcids":["https://orcid.org/0000-0001-5148-8876"]},"institutions":[{"id":"https://openalex.org/I72227227","display_name":"Makerere University","ror":"https://ror.org/03dmz0111","country_code":"UG","type":"education","lineage":["https://openalex.org/I72227227"]}],"countries":["UG"],"is_corresponding":false,"raw_author_name":"Joseph Olobo","raw_affiliation_strings":["Department of Medical Microbiology, Leishmaniasis Unit, College of Health Sciences, Makerere University, Kampala, Uganda"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Microbiology, Leishmaniasis Unit, College of Health Sciences, Makerere University, Kampala, Uganda","institution_ids":["https://openalex.org/I72227227"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5031353369","display_name":"Raymond Omollo","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1298973761","display_name":"Drugs for Neglected Diseases Initiative","ror":"https://ror.org/022mz6y25","country_code":"CH","type":"nonprofit","lineage":["https://openalex.org/I1298973761"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Raymond Omollo","raw_affiliation_strings":["Drugs for Neglected Diseases Initiative, Nairobi, Kenya"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Drugs for Neglected Diseases Initiative, Nairobi, Kenya","institution_ids":["https://openalex.org/I1298973761"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012378695","display_name":"Alexandra Solomos","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1298973761","display_name":"Drugs for Neglected Diseases Initiative","ror":"https://ror.org/022mz6y25","country_code":"CH","type":"nonprofit","lineage":["https://openalex.org/I1298973761"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Alexandra Solomos","raw_affiliation_strings":["Drugs for Neglected Diseases Initiative, Geneva, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Drugs for Neglected Diseases Initiative, Geneva, Switzerland","institution_ids":["https://openalex.org/I1298973761"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5043714917","display_name":"Anke E Kip","orcid":"https://orcid.org/0000-0002-7093-8075","observed_orcids":["https://orcid.org/0000-0002-7093-8075"]},"institutions":[{"id":"https://openalex.org/I2898336195","display_name":"The Netherlands Cancer Institute","ror":"https://ror.org/03xqtf034","country_code":"NL","type":"healthcare","lineage":["https://openalex.org/I2898336195"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"Anke E Kip","raw_affiliation_strings":["Department of Pharmacy & Pharmacology, Antoni van Leeuwenhoek Hospital/the Netherlands Cancer Institute, Amsterdam"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pharmacy & Pharmacology, Antoni van Leeuwenhoek Hospital/the Netherlands Cancer Institute, Amsterdam","institution_ids":["https://openalex.org/I2898336195"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5076831851","display_name":"George Kirigi","orcid":"https://orcid.org/0000-0002-4324-6137","observed_orcids":["https://orcid.org/0000-0002-4324-6137"]},"institutions":[{"id":"https://openalex.org/I2841861","display_name":"Kenya Medical Research Institute","ror":"https://ror.org/04r1cxt79","country_code":"KE","type":"facility","lineage":["https://openalex.org/I2841861"]}],"countries":["KE"],"is_corresponding":false,"raw_author_name":"George Kirigi","raw_affiliation_strings":["Centre for Clinical Research, Kenya Medical Research Institute, Nairobi"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Centre for Clinical Research, Kenya Medical Research Institute, Nairobi","institution_ids":["https://openalex.org/I2841861"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5036492095","display_name":"Patrick Sagaki","orcid":"https://orcid.org/0009-0005-3055-851X","observed_orcids":["https://orcid.org/0009-0005-3055-851X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Patrick Sagaki","raw_affiliation_strings":["Amudat Hospital, Uganda"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Amudat Hospital, Uganda","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5041401888","display_name":"Robert Kimutai","orcid":"https://orcid.org/0000-0002-1039-378X","observed_orcids":["https://orcid.org/0000-0002-1039-378X"]},"institutions":[{"id":"https://openalex.org/I1298973761","display_name":"Drugs for Neglected Diseases Initiative","ror":"https://ror.org/022mz6y25","country_code":"CH","type":"nonprofit","lineage":["https://openalex.org/I1298973761"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Robert Kimutai","raw_affiliation_strings":["Drugs for Neglected Diseases Initiative, Nairobi, Kenya"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Drugs for Neglected Diseases Initiative, Nairobi, Kenya","institution_ids":["https://openalex.org/I1298973761"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5040102108","display_name":"Lilian Were","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1298973761","display_name":"Drugs for Neglected Diseases Initiative","ror":"https://ror.org/022mz6y25","country_code":"CH","type":"nonprofit","lineage":["https://openalex.org/I1298973761"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Lilian Were","raw_affiliation_strings":["Drugs for Neglected Diseases Initiative, Nairobi, Kenya"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Drugs for Neglected Diseases Initiative, Nairobi, Kenya","institution_ids":["https://openalex.org/I1298973761"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5085991920","display_name":"Truphosa Omollo","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1298973761","display_name":"Drugs for Neglected Diseases Initiative","ror":"https://ror.org/022mz6y25","country_code":"CH","type":"nonprofit","lineage":["https://openalex.org/I1298973761"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Truphosa Omollo","raw_affiliation_strings":["Drugs for Neglected Diseases Initiative, Nairobi, Kenya"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Drugs for Neglected Diseases Initiative, Nairobi, Kenya","institution_ids":["https://openalex.org/I1298973761"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072332792","display_name":"Thaddaeus Egondi","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1298973761","display_name":"Drugs for Neglected Diseases Initiative","ror":"https://ror.org/022mz6y25","country_code":"CH","type":"nonprofit","lineage":["https://openalex.org/I1298973761"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Thaddaeus W Egondi","raw_affiliation_strings":["Drugs for Neglected Diseases Initiative, Nairobi, Kenya"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Drugs for Neglected Diseases Initiative, Nairobi, Kenya","institution_ids":["https://openalex.org/I1298973761"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5063364805","display_name":"Monique K. Wasunna","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1298973761","display_name":"Drugs for Neglected Diseases Initiative","ror":"https://ror.org/022mz6y25","country_code":"CH","type":"nonprofit","lineage":["https://openalex.org/I1298973761"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Monique Wasunna","raw_affiliation_strings":["Drugs for Neglected Diseases Initiative, Nairobi, Kenya"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Drugs for Neglected Diseases Initiative, Nairobi, Kenya","institution_ids":["https://openalex.org/I1298973761"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5024500372","display_name":"Jorge Alvar","orcid":"https://orcid.org/0000-0003-2920-742X","observed_orcids":["https://orcid.org/0000-0003-2920-742X"]},"institutions":[{"id":"https://openalex.org/I1298973761","display_name":"Drugs for Neglected Diseases Initiative","ror":"https://ror.org/022mz6y25","country_code":"CH","type":"nonprofit","lineage":["https://openalex.org/I1298973761"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Jorge Alvar","raw_affiliation_strings":["Drugs for Neglected Diseases Initiative, Geneva, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Drugs for Neglected Diseases Initiative, Geneva, Switzerland","institution_ids":["https://openalex.org/I1298973761"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5054194543","display_name":"Thomas P. C. Dorlo","orcid":"https://orcid.org/0000-0003-3076-8435","observed_orcids":["https://orcid.org/0000-0003-3076-8435"]},"institutions":[{"id":"https://openalex.org/I2898336195","display_name":"The Netherlands Cancer Institute","ror":"https://ror.org/03xqtf034","country_code":"NL","type":"healthcare","lineage":["https://openalex.org/I2898336195"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"Thomas P C Dorlo","raw_affiliation_strings":["Department of Pharmacy & Pharmacology, Antoni van Leeuwenhoek Hospital/the Netherlands Cancer Institute, Amsterdam"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pharmacy & Pharmacology, Antoni van Leeuwenhoek Hospital/the Netherlands Cancer Institute, Amsterdam","institution_ids":["https://openalex.org/I2898336195"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5070984672","display_name":"Fabiana Piovesan Alves","orcid":"https://orcid.org/0000-0001-6213-5224","observed_orcids":["https://orcid.org/0000-0001-6213-5224"]},"institutions":[{"id":"https://openalex.org/I1298973761","display_name":"Drugs for Neglected Diseases Initiative","ror":"https://ror.org/022mz6y25","country_code":"CH","type":"nonprofit","lineage":["https://openalex.org/I1298973761"]}],"countries":["CH"],"is_corresponding":true,"raw_author_name":"Fabiana Alves","raw_affiliation_strings":["Drugs for Neglected Diseases Initiative, Geneva, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Drugs for Neglected Diseases Initiative, Geneva, Switzerland","institution_ids":["https://openalex.org/I1298973761"]}]}],"institutions":[],"countries_distinct_count":4,"institutions_distinct_count":4,"corresponding_author_ids":["https://openalex.org/A5070984672"],"corresponding_institution_ids":["https://openalex.org/I1298973761"],"apc_list":{"value":4763,"currency":"USD","value_usd":4763},"apc_paid":{"value":4763,"currency":"USD","value_usd":4763},"fwci":6.069,"has_fulltext":true,"cited_by_count":59,"citation_normalized_percentile":{"value":0.96883999,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":95,"max":99},"biblio":{"volume":"68","issue":"9","first_page":"1530","last_page":"1538"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10823","display_name":"Research on Leishmaniasis Studies","score":0.9961000084877014,"subfield":{"id":"https://openalex.org/subfields/2739","display_name":"Public Health, Environmental and Occupational Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10823","display_name":"Research on Leishmaniasis Studies","score":0.9961000084877014,"subfield":{"id":"https://openalex.org/subfields/2739","display_name":"Public Health, Environmental and Occupational Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12547","display_name":"Pharmaceutical studies and practices","score":0.0032999999821186066,"subfield":{"id":"https://openalex.org/subfields/2735","display_name":"Pediatrics, Perinatology and Child Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11702","display_name":"Parasitic Diseases Research and Treatment","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/miltefosine","display_name":"miltefosine","score":0.8790000081062317},{"id":"https://openalex.org/keywords/visceral-leishmaniasis","display_name":"visceral leishmaniasis","score":0.9959999918937683},{"id":"https://openalex.org/keywords/pediatric-dosing","display_name":"pediatric dosing","score":0.8119999766349792},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.8989999890327454},{"id":"https://openalex.org/keywords/drug-accumulation","display_name":"drug accumulation","score":0.6899999976158142},{"id":"https://openalex.org/keywords/cure-rate","display_name":"cure rate","score":0.781000018119812},{"id":"https://openalex.org/keywords/treatment-safety","display_name":"treatment safety","score":0.6669999957084656},{"id":"https://openalex.org/keywords/east-africa","display_name":"East Africa","score":0.5289999842643738}],"concepts":[{"id":"https://openalex.org/C2781417161","wikidata":"https://www.wikidata.org/wiki/Q411787","display_name":"Miltefosine","level":4,"score":0.986081600189209},{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.9242713451385498},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7905303239822388},{"id":"https://openalex.org/C2778689377","wikidata":"https://www.wikidata.org/wiki/Q2046113","display_name":"Visceral leishmaniasis","level":3,"score":0.7064669728279114},{"id":"https://openalex.org/C2781413609","wikidata":"https://www.wikidata.org/wiki/Q7308373","display_name":"Regimen","level":2,"score":0.5934268236160278},{"id":"https://openalex.org/C2778715236","wikidata":"https://www.wikidata.org/wiki/Q55622662","display_name":"Discontinuation","level":2,"score":0.49583205580711365},{"id":"https://openalex.org/C2776555147","wikidata":"https://www.wikidata.org/wiki/Q331283","display_name":"Leishmaniasis","level":2,"score":0.4952496588230133},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.4397626221179962},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.39149588346481323},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.3375331461429596},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.1608593463897705}],"mesh":[{"descriptor_ui":"D000351","descriptor_name":"Africa, Eastern","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000981","descriptor_name":"Antiprotozoal Agents","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D000981","descriptor_name":"Antiprotozoal Agents","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D000981","descriptor_name":"Antiprotozoal Agents","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D002648","descriptor_name":"Child","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002675","descriptor_name":"Child, Preschool","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004334","descriptor_name":"Drug Administration Schedule","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007893","descriptor_name":"Leishmania donovani","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D007893","descriptor_name":"Leishmania donovani","qualifier_ui":"Q000254","qualifier_name":"growth & development","is_major_topic":false},{"descriptor_ui":"D007893","descriptor_name":"Leishmania donovani","qualifier_ui":"Q000472","qualifier_name":"pathogenicity","is_major_topic":false},{"descriptor_ui":"D007898","descriptor_name":"Leishmaniasis, Visceral","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D007898","descriptor_name":"Leishmaniasis, Visceral","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D007898","descriptor_name":"Leishmaniasis, Visceral","qualifier_ui":"Q000469","qualifier_name":"parasitology","is_major_topic":false},{"descriptor_ui":"D007898","descriptor_name":"Leishmaniasis, Visceral","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010767","descriptor_name":"Phosphorylcholine","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":true},{"descriptor_ui":"D010767","descriptor_name":"Phosphorylcholine","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D010767","descriptor_name":"Phosphorylcholine","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D010767","descriptor_name":"Phosphorylcholine","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019540","descriptor_name":"Area Under Curve","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D061214","descriptor_name":"Patient Safety","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":3,"locations":[{"id":"doi:10.1093/cid/ciy747","doi":"https://doi.org/10.1093/cid/ciy747","is_oa":true,"landing_page_url":"https://doi.org/10.1093/cid/ciy747","pdf_url":"https://academic.oup.com/cid/article-pdf/68/9/1530/28520743/ciy747.pdf","source":{"id":"https://openalex.org/S72350973","display_name":"Clinical Infectious Diseases","issn_l":"1058-4838","issn":["1058-4838","1537-6591"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Infectious Diseases","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:6481997","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/6481997","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clin Infect Dis","raw_type":"Text"},{"id":"pmid:30188978","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/30188978","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical infectious diseases : an official publication of the Infectious Diseases Society of America","raw_type":"Clinical Trial, Phase II"}],"best_oa_location":{"id":"doi:10.1093/cid/ciy747","doi":"https://doi.org/10.1093/cid/ciy747","is_oa":true,"landing_page_url":"https://doi.org/10.1093/cid/ciy747","pdf_url":"https://academic.oup.com/cid/article-pdf/68/9/1530/28520743/ciy747.pdf","source":{"id":"https://openalex.org/S72350973","display_name":"Clinical Infectious Diseases","issn_l":"1058-4838","issn":["1058-4838","1537-6591"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Infectious Diseases","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320307856","display_name":"World Health Organization","ror":"https://ror.org/01f80g185"},{"id":"https://openalex.org/F4320319996","display_name":"Department for International Development, UK Government","ror":"https://ror.org/05rf29967"},{"id":"https://openalex.org/F4320320300","display_name":"European Commission","ror":"https://ror.org/00k4n6c32"},{"id":"https://openalex.org/F4320321114","display_name":"Bundesministerium f\u00fcr Bildung und Forschung","ror":"https://ror.org/04pz7b180"},{"id":"https://openalex.org/F4320321637","display_name":"Department for International Development","ror":"https://ror.org/05rf29967"},{"id":"https://openalex.org/F4320324643","display_name":"Ministerie van Buitenlandse Zaken","ror":"https://ror.org/03rx2ty86"},{"id":"https://openalex.org/F4320326791","display_name":"Agence Fran\u00e7aise de D\u00e9veloppement","ror":"https://ror.org/04tqhj682"},{"id":"https://openalex.org/F4320328261","display_name":"Drugs for Neglected Diseases initiative","ror":"https://ror.org/022mz6y25"}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2890715470.pdf","grobid_xml":"https://content.openalex.org/works/W2890715470.grobid-xml"},"referenced_works_count":16,"referenced_works":["https://openalex.org/W2016587111","https://openalex.org/W2021443540","https://openalex.org/W2038565126","https://openalex.org/W2041065394","https://openalex.org/W2063982195","https://openalex.org/W2066382164","https://openalex.org/W2066680067","https://openalex.org/W2107915297","https://openalex.org/W2109788582","https://openalex.org/W2121179442","https://openalex.org/W2126420606","https://openalex.org/W2148707789","https://openalex.org/W2158168571","https://openalex.org/W2272820937","https://openalex.org/W2519666645","https://openalex.org/W2750822783"],"related_works":["https://openalex.org/W3048539852","https://openalex.org/W7098400084","https://openalex.org/W2041065394","https://openalex.org/W2031425275","https://openalex.org/W7125498193","https://openalex.org/W4386877612","https://openalex.org/W2121179442","https://openalex.org/W3084284643","https://openalex.org/W2009000955","https://openalex.org/W2150604586"],"abstract_inverted_index":{"BACKGROUND:":[0],"Convenient,":[1],"safe,":[2],"and":[3,99,194,206],"effective":[4],"treatments":[5],"for":[6,34,111,229],"visceral":[7,61,234],"leishmaniasis":[8],"in":[9,26,28,38,48,57,170,244],"Eastern":[10,230],"African":[11,231],"children":[12,59,112,232],"are":[13],"lacking.":[14],"Miltefosine,":[15],"the":[16,92,122,146,215,225],"only":[17],"oral":[18],"treatment,":[19],"failed":[20],"to":[21,66,166,192],"achieve":[22],"adequate":[23],"efficacy,":[24],"particularly":[25],"children,":[27],"whom":[29],"linear":[30,82,114,153,210],"dosing":[31,74,203,221,243],"(2.5":[32],"mg/kg/day":[33],"28":[35,69],"days)":[36],"resulted":[37],"a":[39,53,77],"59%":[40],"cure":[41,157],"rate,":[42],"with":[43,60,128,152,233],"lower":[44],"systemic":[45,79],"exposure":[46,80,120,150,208,217],"than":[47,81,107,209],"adults.":[49,171],"METHODS:":[50],"We":[51],"conducted":[52],"Phase":[54],"II":[55],"trial":[56],"30":[58],"leishmaniasis,":[62],"aged":[63],"4-12":[64],"years,":[65],"test":[67],"whether":[68],"days":[70,97],"of":[71,124,149,227,238],"allometric":[72,242],"miltefosine":[73,202,228,239],"safely":[75,223],"achieves":[76],"higher":[78,106,129],"dosing.":[83,154],"RESULTS:":[84],"Miltefosine":[85,119],"accumulated":[86],"during":[87],"treatment.":[88],"Median":[89],"areas":[90],"under":[91],"concentration":[93,102],"time":[94],"curve":[95],"from":[96],"0-210":[98],"plasma":[100,131],"maximum":[101],"values":[103],"were":[104,142,173,185,190,197],"slightly":[105],"those":[108],"reported":[109],"previously":[110,168],"on":[113,133],"dosing,":[115,211],"but":[116,179],"not":[117,213],"dose-proportionally.":[118],"at":[121],"start":[123],"treatment":[125,182,193],"was":[126,159],"increased,":[127],"median":[130],"concentrations":[132],"day":[134],"7":[135],"(5.88":[136],"versus":[137],"2.67":[138],"\u03bcg/mL).":[139],"Concentration-time":[140],"curves":[141],"less":[143],"variable,":[144],"avoiding":[145],"low":[147],"levels":[148],"observed":[151],"The":[155,219],"210-day":[156],"rate":[158],"90%":[160],"(95%":[161],"confidence":[162],"interval,":[163],"73-98%),":[164],"similar":[165],"that":[167],"described":[169],"There":[172,184],"19":[174],"treatment-related":[175],"adverse":[176],"events":[177],"(AEs),":[178],"none":[180],"caused":[181],"discontinuation.":[183],"2":[186],"serious":[187],"AEs:":[188],"both":[189,195],"unrelated":[191],"patients":[196],"fully":[198],"recovered.":[199],"CONCLUSIONS:":[200],"Allometric":[201],"achieved":[204],"increased":[205,224],"less-variable":[207],"though":[212],"reaching":[214],"expected":[216],"levels.":[218],"new":[220],"regimen":[222],"efficacy":[226],"leishmaniasis.":[235],"Further":[236],"development":[237],"should":[240],"adopt":[241],"pediatric":[245],"patients.":[246],"CLINICAL":[247],"TRIALS":[248],"REGISTRATION:":[249],"NCT02431143.":[250]},"counts_by_year":[{"year":2026,"cited_by_count":5},{"year":2025,"cited_by_count":6},{"year":2024,"cited_by_count":5},{"year":2023,"cited_by_count":11},{"year":2022,"cited_by_count":6},{"year":2021,"cited_by_count":12},{"year":2020,"cited_by_count":11},{"year":2019,"cited_by_count":3}],"updated_date":"2026-11-07T11:25:07.637180","created_date":"2018-09-27T00:00:00"}